Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Imatinib Mesylate × Other neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 86 Myeloid 63 Sarcoma 40 Gastrointestinal 32 Lymphoid 22 Thoracic 14 CNS 11 Dermatologic 9 Genitourinary 8 Gynecologic 7 Other solid neoplasm 5 Breast 5 Tumor-Agnostic 4 Head & Neck 4 Plasma cell 1 Other neoplasm 1 Endocrine 1

Conditions

Rare Malignant Neoplasm 1

Interventions

Cyclophosphamide 7 fludarabine phosphate 6 Peripheral Blood Stem Cell Transplantation 6 Whole-Body Irradiation 5 Tacrolimus 4 Mycophenolic Acid 4 Methotrexate 4 Melphalan 4 Busulfan 4 Sulindac 3 Paclitaxel 3 Cyclosporine 3 Cisplatin 3 Capecitabine 3 Antilymphocyte Serum 3 toripalimab 2 sintilimab 2 fludarabine 2 Taxes 2 Surveys and Questionnaires 2 Specimen Handling 2 Sirolimus 2 Radiotherapy 2 Patient Reported Outcome Measures 2 Nivolumab 2 Mesna 2 Magnetic Resonance Spectroscopy 2 Hyperthermic Intraperitoneal Chemotherapy 2 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2 Gene Expression Profiling 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡